Could cause temporary or reversible harm; serious harm is unlikely.
Presence of foreign substance: Product complaint of foreign material in reconstituted bottle.
| Brand name | CEFDINIR |
| Generic name | CEFDINIR |
| Active ingredient(s) | CEFDINIR |
| Distributed by / for | Lupin Pharmaceuticals, Inc., Baltimore, Maryland 21202, United States |
| NDC | 68180-722-04 |
| Full product label | Cefdinir for Oral Suspension USP 125 mg/5 mL (60 mL when reconstituted), 60 mL bottle, Rx only, Manufactured for: Lupin Pharmaceuticals, Inc., Baltimore, Maryland 21202, United States, Manufactured by: Lupin Limited, Mandideep 462 046, India, NDC 68180-722-04 |
| Recalling firm | Lupin Pharmaceuticals Inc. |
| Distribution | USA nationwide |
| Quantity | 17,040 bottles |
| Recall initiated | 2024-04-24 |
| Report date | 2024-05-22 |
| Recall completed | 2025-04-29 |
| Recall number | D-0497-2024 |
| Classification | Class II |
| FDA status | Terminated |
| Origin on file | Baltimore MD United States |
Source: U.S. FDA enforcement database (openFDA). Look this up on the official FDA recalls site ↗